Literature DB >> 8688152

Expression of oxidative phosphorylation genes in renal tumors and tumoral cell lines.

H Faure Vigny1, A Heddi, S Giraud, D Chautard, G Stepien.   

Abstract

To investigate the regulation of genes encoding the proteins involved in energy metabolism in cancer cells, we studied the expression of several mitochondrial and nuclear genes involved in ATP production. Northern blot analysis was performed on renal tumors of different types: a clear cell carcinoma, an oncocytoma, and urothelial tumors at two different stages. The steady-state transcript patterns were compared with those observed in cell lines derived from renal tumors and in transformed cell lines. Striking differences were revealed among the three types of tumors, their respective controls, and the cultured renal cells. The levels of all mitochondrial transcripts were lower in tumor biopsies and tumoral cell lines than in the normal cell types. Moreover, a higher transcript level of nuclear genes involved in oxidative phosphorylation was observed in the oncocytomas and in the more malignant urothelial tumor. Different transcript patterns were observed in each of the tumoral and transformed cell lines, explaining the difference in metabolism between the different tumors and the tumoral or transformed cell lines. In particular, a high transcript level for the adenine nucleotide translocator isoform 2(ANT2) gene, which is usually not expressed in differentiated cells, was observed in oncocytoma and malignant urothelial renal tumor. This phenomenon was also observed in renal carcinoma cell lines and transformed cells. These data provide the first argument for the involvement of the ANT2 protein in glycolytic ATP uptake in cancer cell mitochondria and suggest a possible ANT2 antisense strategy for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8688152     DOI: 10.1002/(SICI)1098-2744(199607)16:3<165::AID-MC7>3.0.CO;2-G

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  20 in total

Review 1.  Insights into the mitochondrial signaling pathway: what lessons for chemotherapy?

Authors:  Catherine Brenner; Morgane Le Bras; Guido Kroemer
Journal:  J Clin Immunol       Date:  2003-03       Impact factor: 8.317

2.  ANT2 isoform required for cancer cell glycolysis.

Authors:  Arnaud Chevrollier; Dominique Loiseau; Béatrice Chabi; Gilles Renier; Olivier Douay; Yves Malthièry; Georges Stepien
Journal:  J Bioenerg Biomembr       Date:  2005-10       Impact factor: 2.945

Review 3.  Mitochondrial biogenesis in the liver during development and oncogenesis.

Authors:  J M Cuezva; L K Ostronoff; J Ricart; M López de Heredia; C M Di Liegro; J M Izquierdo
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

4.  Treatment with mANT2 shRNA enhances antitumor therapeutic effects induced by MUC1 DNA vaccination.

Authors:  Yun Choi; Yong H Jeon; Ji-Young Jang; June-Key Chung; Chul-Woo Kim
Journal:  Mol Ther       Date:  2010-11-09       Impact factor: 11.454

5.  Biochemical evidence of the interactions of membrane type-1 matrix metalloproteinase (MT1-MMP) with adenine nucleotide translocator (ANT): potential implications linking proteolysis with energy metabolism in cancer cells.

Authors:  Ilian A Radichev; Albert G Remacle; Nor Eddine Sounni; Sergey A Shiryaev; Dmitri V Rozanov; Wenhong Zhu; Natalya V Golubkova; Tatiana I Postnova; Vladislav S Golubkov; Alex Y Strongin
Journal:  Biochem J       Date:  2009-04-28       Impact factor: 3.857

6.  Mutation of mitochondria genome: trigger of somatic cell transforming to cancer cell.

Authors:  Du Jianping
Journal:  Int Arch Med       Date:  2010-02-05

7.  Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.

Authors:  Ji-Young Jang; Yoon-Kyung Jeon; Yun Choi; Chul-Woo Kim
Journal:  Mol Cancer       Date:  2010-09-28       Impact factor: 27.401

8.  Clinico-pathological features of a series of 11 oncocytic endocrine tumours of the pancreas.

Authors:  Marco Volante; Stefano La Rosa; Isabella Castellano; Giovanna Finzi; Carlo Capella; Gianni Bussolati
Journal:  Virchows Arch       Date:  2006-02-21       Impact factor: 4.064

9.  NDUFA4 expression in clear cell renal cell carcinoma is predictive for cancer-specific survival.

Authors:  Franziska E Müller; Martin Braun; Isabella Syring; Niklas Klümper; Doris Schmidt; Sven Perner; Stefan Hauser; Stefan C Müller; Jörg Ellinger
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

10.  ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma.

Authors:  Ji-Young Jang; Young-Sin Lee; Yoon-Kyung Jeon; Kyoungbun Lee; Ja-June Jang; Chul-Woo Kim
Journal:  Exp Mol Med       Date:  2013-01-10       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.